SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval

Charlotte Denise Jeffers[1], Courtney Lawn-Heath[2], Regan I. Butterfield[3], John M. Hoffman[3,4], and Peter J.H. Scott[5]

[1]Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; [2]Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; [3]Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; [4]Department of Radiology and Imaging Sciences, University of Utah School of Medicine, Salt Lake City, Utah; and [5]Department of Radiology, University of Michigan, Ann Arbor, Michigan

The process of bringing a new drug to market is complex and has recently necessitated a new drug-discovery paradigm for the pharmaceutical industry that is both more efficient and more economical. Key to this task has been the increasing use of nuclear medicine and molecular imaging to support drug discovery efforts by answering critical questions on the pathway to development and approval of a new therapeutic drug. Some of these questions include whether the new drug reaches its intended target in the body at sufficient levels to effectively treat or diagnose disease without unacceptable toxicity; how the drug is absorbed, metabolized, and excreted; and what the effective dose is in humans. To conduct the appropriate imaging studies to answer such questions, pharmaceutical companies are increasingly partnering with molecular imaging departments. Nuclear medicine technologists are critical to this process, as they perform scans to collect the qualitative and quantitative imaging data used to measure study endpoints. This article describes preclinical and clinical research trials and provides an overview of the different ways that radiopharmaceuticals are used to answer critical questions during therapeutic drug development.

Key Words: clinical research; nuclear medicine; PET and SPECT; drug development; clinical trials

For pharmaceutical companies, the process of discovering a new diagnostic or therapeutic drug and developing it for market is enormously complex (Fig. 1) and includes preclinical testing, investigational-new-drug (IND) applications, clinical trials, new-drug applications (NDAs), marketing approval from the U.S. Food and Drug Administration (FDA), and postmarketing studies. The goal is to bring safe and effective drugs to market as quickly as possible, but it can take up to 10 y to complete this drug development process, and the lifetime of a U.S. patent (during which pharmaceutical companies need to complete drug discovery, translation, and approval; establish the drug's market share; recoup the research investment; and turn a profit) is only 20 y. Recent studies estimate the average cost of therapeutic drug development at $1.3 billion per drug, but it can be as high as $5.5 billion (*1,2*). This challenge is further exacerbated when promising drug candidates fail to meet prespecified endpoints in later-stage clinical trials after many years of expensive investment. Reimbursement from the Centers for Medicare and Medicaid Services and other insurance carriers also goes through a review process.

These challenges have necessitated a new drug-development paradigm for the pharmaceutical industry that is both more efficient and more economical, and as a result, new technologies are being used to reduce both the costs and the risks associated with drug development. Molecular imaging and nuclear medicine are tools that play a key role in modern drug development because of their ability to address important questions at each step of the drug discovery process (*2,3*). For example, imaging studies costing a few tens to hundreds of thousands of dollars enable companies to reduce risk and more confidently make key go/no-go decisions about advancing drugs to clinical studies costing millions to billions of dollars (depending on size and scope). Such imaging studies require access to different radiopharmaceuticals (e.g., established radiotracers, new radiotracers, and radiolabeled drug candidates) and can be both preclinical and clinical. For example, early drug discovery efforts involve preclinical studies (e.g., in vitro autoradiography, in vivo animal imaging, and ex vivo biodistribution), whereas later drug development trials pivot to clinical studies on human volunteers (phase I, II, and III clinical trials

FIGURE 1. Drug development process. A(NDA) = abbreviated NDA; cGMP = current good manufacturing practice; CMS = Centers for Medicare and Medicaid Services.

conducted under approved IND applications). On completion of phase III studies, an NDA can be filed and, once approved, give the sponsor marketing authorization for the drug. Post-marketing phase IV trials may be required by the FDA for long-term surveillance of drug safety and efficacy.

In this primer, we describe regulatory and logistical considerations for nuclear medicine departments to participate in preclinical and clinical research, as well as an overview of the different ways that radiopharmaceuticals can be used to answer critical questions pertaining to therapeutic drug development (2,3). This paper is a companion to other articles in this series published to date (4).

TYPES OF IMAGING STUDIES CONDUCTED DURING DRUG DEVELOPMENT PROCESS

Nuclear medicine imaging (with PET and SPECT) enables industry and academic teams to answer questions central to new-drug development. PET and SPECT are increasingly used to answer questions during both preclinical in vitro (cells) and in vivo (animal models) studies and during clinical trials (human research subjects), including the following: Does a drug reach the tissue of interest in pharmacologically active concentrations? Does the drug go anywhere else in the body that could cause unwanted side effects? Does the molecule engage with the target (e.g., receptor or protein) of interest? What is the quantitative relationship between the extent of the drug's interaction with the target and the dose administered to a patient (e.g., receptor occupancy)? Can the pharmacologic effects of a therapeutic dose be determined using an imaging biomarker (e.g., tumor shrinkage or ^{18}F-FDG metabolism and uptake (3)), and how long do these effects persist? The answers to these questions are critical to translating a drug to initial clinical trials, as well as to advancing the drug through clinical trials (phases I–III), and imaging offers a powerful means for drug discovery teams to address such questions.

The questions concerning the distribution and target engagement of a drug can often be answered by labeling a drug molecule itself. For example, radiolabeling of a drug with a PET radionuclide, such as ^{11}C, can be accomplished without altering the properties of the drug. Since it is estimated that about 20% of prescribed drugs and about 30% of leading blockbuster drugs contain a fluorine atom (5), in such cases the same can also be accomplished with ^{18}F (6). The labeled drug can then be used in preclinical and clinical biodistribution studies.

PET imaging can also be used to quantify the pharmacologic effects of a therapeutic dose. Such imaging capitalizes on the concept of biologic markers (i.e., biomarkers). A biomarker is an objective measurement that is an indicator of a biologic process in a patient and can serve as an indicator of health. Classic biomarkers are based on laboratory tests (e.g., blood, urine, and tissue biopsy), whereas an imaging biomarker is a measurement of a biologic process, such as quantification of amyloid burden using amyloid PET. Frequently, these types of studies might use companion PET radiotracers rather than a radiolabeled drug. Before commencing such studies, it is necessary to confirm that a radiotracer is appropriate for that purpose. When validating a PET tracer, a test–retest experiment is usually conducted to measure the repeatability of the measurements and determine within-subject variability (7). The test–retest is particularly important if a PET radiotracer is to be used in studies involving multiple measurements on the same subject (e.g., receptor occupancy or before and after a therapeutic intervention).

If an imaging biomarker exists for a given condition, it can be used to diagnose disease and both predict and monitor patient response to experimental new therapeutics in clinical trials. Extending the latter concept further, imaging biomarkers can also be used as a surrogate endpoint in a clinical trial. A surrogate endpoint is defined by the FDA as "a clinical trial endpoint used as a substitute for a direct measure of how a patient feels, functions, or survives" (8). Imaging biomarkers and surrogate endpoints are recognized by the agency and have been widely used in the drug approval and licensure process (8,9). The main difference between an imaging biomarker and a surrogate endpoint is the level of validation. For an imaging biomarker to function as a surrogate endpoint, there must be clinical trials demonstrating the relationship between the imaging biomarker and the true clinical endpoint. Imaging biomarkers have been reviewed (10), and in the case of cancer trials, an imaging biomarker road map has been established (11). Examples of imaging biomarkers used as surrogate endpoints include amyloid imaging (12), assessment of tumor response (13–15), and ^{11}C-raclopride PET for antipsychotic efficacy (16,17).

REGULATORY CONSIDERATIONS

Use of nuclear medicine imaging techniques to support drug development involves both preclinical and clinical

studies. Such work must be conducted in compliance with applicable institutional, state, and federal regulations governing the use of radioactive material, as well as the rules and regulations describing responsible and ethical conduct in animal and human research. These various regulatory requirements are summarized briefly here and are covered in detail in other articles in this series (4).

Radioactive materials need to be handled under the auspices of approved radioactive materials licenses granted by the Nuclear Regulatory Commission or the local state government for agreement states. Such work must also be performed according to the as-low-as-reasonably-achievable principles, which involve making every reasonable effort to ensure that worker exposures to ionizing radiation are as low as practical.

In the United States, PET radiopharmaceuticals are prepared according to the principles of current good manufacturing practices outlined in the *U.S. Pharmacopeia* chapter <1823> (18) or chapter <825> (19) and in part 212 of title 21 of *Code of Federal Regulations* (CFR) (20). Other radiopharmaceuticals (e.g., radiotherapeutics) are often prepared according to requirements outlined in 21 CFR parts 210 (21) and 211 (22). The regulations on current good manufacturing practices cover types of facilities, cleanliness and maintenance of the facilities, laboratory controls, equipment, personnel, training, quality assurance, documentation about materials and processes, drug product controls, packaging and labeling requirements, complaint handling, and record keeping.

Preclinical (animal) studies need to be conducted under the purview of an Institutional Animal Care and Use Committee, and it is typical for pharmaceutical companies to also require collaborating sites to hold Association for Assessment and Accreditation of Laboratory Animal Care International certification. The use of animals to advance medicine and science when there are no nonanimal alternatives remains a critical part of drug development, and preclinical work should be conducted in accord with the highest scientific, humane, and ethical principles as laid out in the *Guide for the Care and Use of Laboratory Animals* (23).

Clinical studies can be conducted only after receiving both FDA approval (e.g., Radioactive Drug Research Committee [RDRC] or IND application) and institutional approval (e.g., Institutional Review Board). Regulations for using radiopharmaceuticals under RDRC approval are described in 21 CFR part 361, whereas the requirements for conducting research under an IND are laid out in 21 CFR part 312. For a detailed description, refer to a companion article in this series (4).

TYPES OF RESEARCH STUDIES

Preclinical Studies

Although nuclear medicine technologists work predominantly in clinical PET imaging, some may find themselves working in academic PET centers or pharmaceutical companies. In the latter instances, they will likely be involved in preclinical studies. Preclinical studies are intended to get earlier answers to many of the same questions that will ultimately be investigated clinically and often to make go/no-go decisions about costly clinical translation. There are 4 main types of preclinical protocols: cell studies, autoradiography experiments with postmortem tissue samples (in vitro or ex vivo), in vivo PET (or SPECT) imaging studies on living animals, and ex vivo biodistribution studies in which animals are euthanized after injection of the tracer, dissected, and their organs counted in a γ-counter to establish the biodistribution and dosimetry of the tracer.

Cell Studies. Cell uptake studies evaluate uptake of a new radiotracer in a cell expressing the drug target of interest. These studies are an economic starting point as they cost considerably less than animal studies. Cell uptake studies offer a preliminary indication of target engagement for a new radiotracer and also help researchers decide promising ones to advance to animal studies.

Binding Affinity Experiments. Binding studies quantify the binding characteristics of a new radiopharmaceutical, such as affinity for its target, which is expressed as the dissociation constant (K_D). Lower K_D values correspond to higher-affinity molecules. Such studies can be conducted using tissue pellets or autoradiography.

Autoradiography Experiments. Autoradiography is a technique in which tissues are incubated with a radiotracer (24) and then exposed to photographic film or phosphor imaging plates to visualize the location of the radiolabeled molecules. In vitro autoradiography studies use postmortem animal or human tissue samples (e.g., a histologic slice of brain or tumor) that have been previously harvested. The radiolabeled molecule is incubated with postmortem tissue samples, giving the molecule time to bind to its target (e.g., receptor or protein). The samples are then washed and exposed to film or plates. In vitro autoradiography does not account for the in vivo environment (e.g., metabolism). If such information is needed, ex vivo autoradiography studies can be undertaken. The radiotracer is first administered intravenously, and after some time point, the animals are euthanized (with or without in vivo PET imaging first) and organs and tissues of interest are harvested for autoradiography. The postmortem tissue samples are washed and exposed to film or plates analogously to in vitro autoradiography.

Autoradiography has been used to quantify and localize drugs in organs, tissues, and cells for decades. The data can be used to determine K_D for a radiotracer, and target engagement of a therapeutic drug can be confirmed by observing a reduction in the signal of the specific radiotracer in the presence of a therapeutic dose (either dosed to the animal [ex vivo autoradiography] or added to the incubation solution [in vitro autoradiography]). Alternatively, the technique can be combined with immunohistochemistry on an adjacent slice of tissue, and colocalization of the autoradiography signal with the fluorescence of target-specific antibodies can be observed. Such datasets are critical in validating a new radiotracer and deciding whether to advance to preclinical and eventual clinical in vivo imaging studies.

In Vivo PET (or SPECT) Imaging Studies. In vivo imaging study logistics closely resemble human studies in that doses, imaging protocols, timing, intravenous catheter placement, interventions, attenuation correction, reconstruction, and radiation safety all have to be accounted for and planned in the same way. An additional consideration with animal work is that, unlike human subjects, animals need to be anesthetized for the duration of the study. Depending on the mechanism of action of a drug, the choice of anesthesia can affect the PET data and may need to be accounted for in study design (25). For preclinical PET imaging, small mice typically receive no more than 9.25 MBq of radiotracer, whereas larger animals receive higher doses depending on weight (e.g., rodents receive ≤37 MBq and primates receive ≤185 MBq). PET scans can be dynamic, and typical scan lengths are 60 min for a ^{11}C-labeled tracer or up to 120 min for an ^{18}F-labeled tracer. Static scans, which could be 5–20 min, can also be acquired at one or more time points after administration of the radiotracer. Baseline scans will give pharmacokinetic and distribution information on a given tracer or labeled drug candidate, whereas intervention studies (e.g., with a dose of therapeutic) can be used to answer questions about specific binding, target engagement, and receptor occupancy at a given dose, among others. In some studies, the animal may be euthanized immediately after the imaging study and organs harvested for further evaluation using autoradiography. Figure 2 shows a baseline nonhuman-primate PET scan obtained with ^{18}F-AH114726, a new radiotracer targeting the γ-aminobutyric acid type A receptor (26). The scan reveals high uptake in the cortical region, which is known to have high expression of γ-aminobutyric acid type A receptors. To confirm selectivity of the new compound for the target, the scan was repeated in the presence of a 1 mg/kg dose of flumazenil, a known selective γ-aminobutyric acid type A receptor antagonist. The repeated scan confirmed target engagement and selectivity of AH114726, as complete displacement of the radiotracer was apparent on dosing with flumazenil.

Biodistribution Studies. Ex vivo biodistribution studies are operationally more complex than in vivo imaging, as they involve euthanizing animals at a predetermined time point after dosing the radiotracer, dissecting them, and counting the individual organs in a γ-counter. Such studies provide comprehensive biodistribution data (percentage injected dose per gram of tissue) that can be input into software programs such as OLINDA (27) to generate the human dosimetry estimates that need to be included in any IND filings supporting translation of PET radiotracers into clinical studies.

Clinical Studies

Clinical studies, using PET, most frequently apply established radiotracers that are either FDA-approved or investigational. Investigational radiotracers can be used under the approval of an institutional RDRC committee or an FDA-approved IND, depending on the intended application (4,28). Approved radiotracers are used under the auspices of either an NDA or, in the case of generic drugs, an abbreviated NDA. The different phases of clinical trials are summarized in Table 1 and described in detail in a previous article in this series (4).

HOW RADIOPHARMACEUTICALS CAN BE DEPLOYED IN RESEARCH

Several types of radiopharmaceuticals are used in imaging collaborations with pharmaceutical companies (Table 2). They include use of FDA-approved products as tracers or biomarkers to study aspects of disease, investigational agents to interrogate biologic systems and functions, investigational imaging or therapeutic radiopharmaceuticals being developed for FDA approval, and radiolabeled drug compounds to study biodistribution and receptor occupancy. The selection of an appropriate imaging agent depends on the study in question and on local availability. For example, different imaging agents might be used at various sites in the same clinical trial, depending on availability from nearby commercial nuclear pharmacies.

FDA-Approved Imaging Radiopharmaceuticals for Diagnosis, Staging, and Monitoring of Therapy

Approved radiopharmaceuticals can be used for diagnosis of disease, staging, and monitoring of response to therapy (experimental or approved). Importantly, if patients respond to therapy they continue receiving the same treatment, whereas if they do not respond they can be switched to alternate therapies rapidly, saving both time and money and


FIGURE 2. Representative coronal small-animal PET images of control animal imaged with ^{18}F-AH114726 at baseline and after displacement with 1 mg/kg dose of flumazenil. (Reprinted with permission of (26).)

TABLE 1
Overview of Clinical Trial Process

Phase	No. of subjects	Scope
0/I	Few dozen (therapeutic); 10–30 (diagnostic)	New drug is first given to small number of people; studies might be exploratory, involving several candidate molecules to select lead for development (46), and are intended to demonstrate safety of new agent and dose-limiting toxicity
II	Few hundred (therapeutic); 20–40 (diagnostic)	Study is undertaken to demonstrate proof of efficacy and to reveal less common side effects; if enough patients benefit from new drug, and side effects are acceptable, then phase III trials can be initiated; additional safety data are obtained
III	Several hundred (therapeutic); 50–100 (diagnostic)	Trials are intended to compare safety and efficacy of new diagnostic or therapeutic agent against standard of care and typically are large and multicenter; research subjects are picked at random to receive standard of care or new treatment; when neither doctor nor subject knows which treatment subject is getting, trial is considered double-masked; additional safety data are obtained, and if new drug is found to be as effective as or more effective than existing drugs, or is safer, NDA can be submitted to FDA
IV	Thousands	Postapproval studies are intended to monitor FDA-approved drugs over long period (e.g., several years)

reducing the duration of unnecessary side effects. Pioneering work was conducted by the team of Van den Abbeele at the Dana-Farber Cancer Institute to diagnose and treat gastrointestinal stromal tumors (GISTs) (28). ^{18}F-FDG PET can be used to diagnose, localize, and stage GISTs and to monitor response to imatinib (Gleevec; Novartis) therapy (Fig. 3). The functional information on tumor metabolism of glucose from serial ^{18}F-FDG scans can be used to detect both short-term

TABLE 2
Radiopharmaceuticals Used in Clinical Trials

Type	Examples
FDA-approved imaging radiopharmaceuticals*	^{18}F-FDG
	^{18}F-florbetapir (Amyvid)
	^{18}F-florbetaben (Neuraceq)
	^{18}F-flutemetamol (Vizamyl)
	^{18}F-flortaucipir (Tauvid)
	^{68}Ga-DOTATATE (NETSPOT; Advanced Accelerator Applications)
	^{64}Cu-DOTATATE (Detectnet; Curium US LLC)
	^{68}Ga-PSMA-11 (University of California San Francisco and UCLA)
	^{18}F-DCFPyL (Pylarify; Progenics Pharmaceuticals, Inc.)
	^{123}I-ioflupane (DaTscan; GE Healthcare)
	^{18}F-fluciclovine (Axumin; Blue Earth Diagnostics)
	^{8}F-fluroestradiol (Cerianna; Zionexa US Corp.)
	^{99m}Tc-sestamibi
	^{18}F-fluorodopa (Feinstein Institutes for Medical Research)
	^{68}Ga-PSMA-gozetotide (Locametz; Novartis)
FDA-approved therapeutic radiopharmaceuticals	^{177}Lu-DOTATATE (Lutathera; Advanced Accelerator Applications)
	^{177}Lu-PSMA-617 (Pluvicto; Novartis)
Investigational agents for research under RDRC or IND	^{11}C-Pittsburgh compound B
	^{18}F-fluorothymidine
	^{18}F-FEOBV
Investigational imaging and therapeutic agents for commercialization	^{18}F-flupiridaz (imaging)
	^{225}Ac-PSMA-617 (therapy)
Investigational radiotracers to support therapeutic trials (e.g., receptor occupancy)	^{18}F-SPARQ
Radiolabeled drugs or drug candidates	^{11}C-ibrutinib
	^{11}C-docetaxel
	^{18}F-lansoprazole

*For diagnosis, staging, and monitoring of therapy or as biomarker or surrogate endpoint.

FIGURE 3. ^{18}F-FDG PET maximum-intensity projections (A–C), axial PET images (D–F), and axial CT images (G–I) through pelvis in patient with metastatic GIST. Normal physiologic ^{18}F-FDG uptake is seen in urinary collecting system in both kidneys (kd), in myocardium (my), and in bladder (bl). (A) Intense ^{18}F-FDG uptake is seen in left lower pelvis and contiguous to right proximal ureter (TU) at baseline before imatinib therapy, consistent with metastatic GIST. (B) Resolution of abnormal ^{18}F-FDG uptake is noted in both tumor masses as early as 1 wk after treatment. (C) Continuous metabolic response to imatinib is seen in this patient 2 mo after initiation of therapy despite presence of residual mass on CT. (Reprinted with permission of (29).)

and long-term tumor responses that may not be obvious with CT. The team noted that ^{18}F-FDG PET responses were apparent even 24 h after the first dose of imatinib. Significant changes in ^{18}F-FDG uptake (>25% decrease in SUV_{max} relative to baseline) were apparent within 1 mo of starting imatinib therapy in all GIST patients who responded. Any lack of response was quickly apparent on the PET scans, such that treatment could be changed to sunitinib (Sutent; Pfizer), which is a second drug approved for treatment of GIST and to which non–imatinib-responding patients may be more sensitive.

Use of FDA-Approved Imaging Agents as Biomarkers or Surrogate Endpoints in Clinical Trials

A recent example of using PET radiotracers to support therapeutic trials applied amyloid imaging (^{18}F-florbetapir [Amyvid; Eli Lilly], ^{18}F-flutemetamol [Vizamyl; GE Healthcare], and ^{18}F-florbetaben [Neuraceq; Life Molecular Imaging]) and tau PET (^{18}F-flortaucipir [Tauvid; Eli Lilly] and MK6240) to support development of Alzheimer disease therapeutics such as aducanumab. Such therapeutic agents are recombinant human monoclonal antibodies that bind aggregated types of β-amyloid that form the hallmark amyloid plaques in Alzheimer disease. PET imaging played a crucial role in confirming the initial eligibility of a given patient to participate in a clinical trial and in monitoring the subsequent response to therapy. In clinical trials of aducanumab, amyloid PET revealed decreases in β-amyloid neuritic plaque accumulation on treatment (Fig. 4) (29).

Investigational Agents for Research Use Under RDRC or IND

Imaging agents can be used for research applications under the approval of an institutional RDRC (30) or under an approved IND (31). To use a radiotracer according to the RDRC mechanism, the following provisions must be met: the research must be considered basic science research and be done for the purpose of advancing scientific knowledge; the research study must be authorized by an FDA-approved RDRC; the pharmacologic dose of the radioactive drug must be known not to cause any clinically detectable pharmacologic effect on humans; and the radiation dose to be administered must be justified by the quality of the study and the information it seeks to obtain. If these provisions cannot be met, an approved IND application is required for the agent before any human research can be conducted (32,33). Academic medical centers frequently have many established radiotracers available for use in RDRC protocols and likely also hold IND approvals for several additional radiotracers. Additional research protocols can be added to INDs by submission of amendments to the FDA. After a radiotracer has been used in humans under an IND, it can be advanced to additional clinical trials with a goal of commercialization. Alternatively, if the pharmacologic dose did not cause any clinically detectable pharmacologic effects, it can subsequently be transitioned to RDRC studies for additional research, assuming the other criteria are met.

The transition from RDRC to IND can be illustrated by ^{18}F-(−)5-fluoroethoxybenzovesamicol (^{18}F-FEOBV), a PET radiotracer that was developed at the University of Michigan and is

FIGURE 4. ^{18}F-florbetapir (Amyvid) amyloid PET images at baseline and 1 y after aducanumab treatment, showing amyloid plaque reduction after different doses of aducanumab but not placebo. (Reprinted with permission of (*30*).)

based on a vesamicol analog used to image the vesicular acetylcholine transporter (*34*). After preclinical development along the lines described in this article, the team wrote an IND and received approval from the FDA to proceed with first-in-humans studies. Whole-body ^{18}F-FEOBV scans were initially conducted on 3 healthy volunteers. Seven additional subjects underwent dynamic brain imaging (Fig. 5), and kinetic modeling revealed agreement between reference tissue modeling and late single-scan imaging. This study allowed quantification of human dosimetry, indicating that more than 400 MBq could be administered without exceeding radiation dose limits. No pharmacologic or physiologic changes were observed after intravenous administration of no more than 1.3 μg of ^{18}F-FEOBV. This information subsequently enabled use of ^{18}F-FEOBV under RDRC approval (and related mechanisms in other countries) by other research teams in the United States and elsewhere (*35–37*). For example, Kanel et al. recently used ^{18}F-FEOBV to investigate age-related declines in regional cholinergic neuron terminal density (Fig. 5) (*38*).

Investigational Imaging and Therapeutic Agents Being Developed for Commercialization

Development of new radiopharmaceuticals for commercialization follows the process illustrated in Figure 1. Since companies do not have access to research subjects, clinical trials are usually conducted in collaboration with academic medical centers. After preclinical work, an IND is obtained to enable clinical trials with new agents to prove safety and efficacy. High-profile examples are the theranostic agents targeting prostate-specific membrane antigen (PSMA) for


FIGURE 5. (Left) ^{18}F-FEOBV PET, MR, and overlay images from healthy control subject. (Reprinted from (*35*).) (Right) Age-related reduced Vesicular acetylcholine transporter binding reductions (Reprinted from (*39*).)

FIGURE 6. ^{68}Ga-PSMA-11 PET before and after treatment with ^{177}Lu-PSMA-617. (Reprinted from (*42*).)

imaging and treatment of prostate cancer. In the case of ^{68}Ga-PSMA-11, after pioneering work from Heidelberg, an NDA for ^{68}Ga-PSMA-11 was obtained by UCLA and the University of California San Francisco through an academic partnership (*39*). They conducted a phase III trial, and separate NDAs for each institution were approved by the FDA. Subsequent approvals for kits to produce ^{68}Ga-PSMA-11 have been obtained by Telix and Novartis, and the agent has been used to image thousands of patients (*40*).

Concurrently with these efforts, ^{177}Lu-PSMA-617 was developed for radiotherapy of prostate cancer. PSMA PET is used to confirm patient eligibility and to monitor response to

FIGURE 7. (Left) ^{18}F-SPARQ PET images of subject who received 100 mg of aprepitant: predosing (top row) and postdosing (bottom row) are shown, with estimated receptor occupancy of 94%. (Right) Relationship between plasma concentration of aprepitant and receptor occupancy. NK1 = neurokinin-1. (Reprinted with permission of (*45*).)

therapy. Phase 2 studies showed promising results (Fig. 6) (*41*), and the rights for development were acquired by Endocyte (later purchased by Novartis). In the large, international, multicenter phase 3 VISION trial, 831 patients underwent randomization. VISION provided evidence for significantly improved progression-free and overall survival in late-stage prostate cancer patients who were treated with ^{177}Lu-PSMA-617 (compared with the standard of care) (*42,43*). FDA approval for ^{177}Lu-PSMA-617 was granted earlier this year.

New Radiotracers Developed to Support Therapeutic Trials

If radiotracers do not exist for a given therapeutic target, it is necessary to develop the appropriate companion diagnostic when PET studies are needed. One seminal report on the use of PET imaging to guide therapeutic development was Merck's work with Emend (aprepitant), a neurokinin 1 receptor antagonist being developed both for treatment of chemotherapy-induced nausea and as an antidepressant (*44*). Instead of labeling the drug itself, Merck developed a companion tracer, ^{18}F-SPARQ (Substance P Antagonist Receptor Quantifier), and used it to determine the receptor occupancy achieved by different doses of Emend in healthy humans. Importantly, greater than 95% receptor occupancy was found at the proposed dose (Fig. 7), indicating the correct dose selection. Merck knew that this dose was effective for managing nausea caused by chemotherapy, moved forward with the antinausea indication, and gained marketing approval from the FDA. In contrast, Merck also knew that the study dose of Emend had no antidepressant effects, and the PET study revealed that a larger dose would not increase receptor occupancy. As such, the results of this study (likely costing tens of thousands of dollars) allowed Merck to cancel development of Emend for depression and save millions of dollars on what would have been a futile phase III trial (*44*).

Radiolabeled Drugs or Drug Candidates

Important questions concerning a drug can be answered by labeling the drug molecule itself. Clinical imaging studies using labeled drugs allow drug developers to obtain information about biodistribution and target engagement.

This information can be used to confirm patient eligibility for a given treatment, as well as to predict response. This approach holds particular promise for anticancer drugs. In a given malignancy, certain chemotherapeutics will be used on the basis of demonstrated clinical efficacy (e.g., tumor response or improved survival). A one-size-fits-all approach has been used in which patients are started on a standard regimen for their cancer. However, failure of a given chemotherapeutic occurs in certain patients because many cancers do not respond consistently. Therefore, nonresponders are often subjected to the psychologic burden of chemotherapy along with frequent associated toxicities without gaining any benefit. In this age of personalized medicine, a new era of chemotherapy that abandons this one-size-fits-all approach is needed. Molecular imaging has an important role to play in this paradigm shift.

Proof of concept for docetaxel has been demonstrated by van der Veldt et al. at VU University Medical Center in Amsterdam. This cytotoxic drug is a taxane that was initially approved for treatment of anthracycline-refractory metastatic breast cancer and has subsequently been approved for treatment of several other cancers (e.g., metastatic prostate cancer, head and neck cancer, and non–small cell lung cancer). However, cancers often do not respond consistently to chemotherapeutics. Docetaxel failure in some patients means that they experience associated toxicities without any benefit. To explore a more personalized approach to deciding which patients would benefit from docetaxel therapy, the team prepared ^{11}C-docetaxel (45). Using PET imaging in conjunction with microdoses of ^{11}C-docetaxel (to eliminate toxicity concerns), the team was able to quantify tumor uptake of the labeled drug across patients. This work showed that ^{11}C-docetaxel PET can be used to predict tumor uptake of the drug during subsequent docetaxel therapy, and the team also demonstrated that high tumor uptake of ^{11}C-docetaxel was related to improved tumor response after treatment.

Going forward, PET with radiolabeled drugs will enable straightforward confirmation of target engagement in humans and, in turn, predict treatment outcome in advance. The work with ^{11}C-docetaxel also suggests that radiolabeled drugs can help to reveal underlying mechanisms of treatment failure in subpopulations of patients (e.g., poor accumulation in a tumor or poor target engagement).

CONCLUSION

The power of nuclear medicine and molecular imaging to provide key information about new therapeutic candidates has become an integral part of the modern drug development paradigm. Preclinical studies can allow early go/no-go decisions about whether to advance a new drug to clinical trials. After clinical translation, imaging can be used to enrich clinical trials, predict response to therapy, monitor response, and obtain valuable information about target engagement and dosing. In this way, it is expected that nuclear medicine and molecular imaging using radiotracers or radiolabeled drugs will continue to provide insights during drug development. When combined with other emerging technologies, this approach will usher in a new era of personalized medicine in which rational treatment choices tailored to individual patients to improve outcomes will replace a one-size-fits-all approach to disease management.

REFERENCES

1. Herper M. The cost of creating a new drug now $5 billion, pushing big pharma to change. Forbes website. https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/?sh=1ec8793613c3. Published August 11, 2013. Accessed September 20, 2022.
2. Donnelly DJ. PET imaging in drug discovery and development. In: Kilbourn MR, Scott PJH, eds. *Handbook of Radiopharmaceuticals: Methodology and Applications*. 2nd ed. John Wiley and Sons Ltd.; 2021:703–725.
3. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. *Clin Cancer Res*. 2005;11:2785–2808.
4. Jeffers CD, Frye SA, Hoffman JM. SNMMI Clinical trials network research series for technologists: clinical research primer—regulatory process, part I: how and when radiopharmaceuticals can be used. *J Nucl Med Technol*. 2022;50:2–9.
5. O'Hagan D. Fluorine in health care: organofluorine containing blockbuster drugs. *J Fluor Chem*. 2010;131:1071–1081.
6. Gillis EP, Eastman KJ, Hill MD, et al. Applications of fluorine in medicinal chemistry. *J Med Chem*. 2015;58:8315–8359.
7. Baumgartner R, Joshi A, Feng D, et al. Statistical evaluation of test-retest studies in PET brain imaging. *EJNMMI Res*. 2018;8:13.
8. Table of surrogate endpoints that were the basis of drug approval or licensure. FDA website. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Updated February 28, 2022. Accessed September 20, 2022.
9. Lal R. FDA facilitates the use of surrogate endpoints in drug development. FDA website. https://www.fda.gov/drugs/fda-facilitates-use-surrogate-endpoints-drug-development-november-5-2018-issue. Updated November 5, 2018. Accessed September 20, 2022.
10. Richter WS. Imaging biomarkers as surrogate endpoints for drug development. *Eur J Nucl Med Mol Imaging*. 2006;33:6–10.
11. O'Connor JP, Aboagye E, Adams J, et al. Imaging biomarker roadmap for cancer studies. *Nat Rev Clin Oncol*. 2017;14:169–186.
12. Scheinin NM, Scheinin M, Rinne JO. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. *Q J Nucl Med Mol Imaging*. 2011;55:265–279.
13. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. *Lancet Oncol*. 2010;11:92–102.
14. Ko CC, Yeh LR, Kuo YT, et al. Imaging biomarkers for evaluating tumor response: RECIST and beyond. *Biomark Res*. 2021;9:52.
15. Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. *J Nucl Med*. 2014;55:525–528.
16. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. *CNS Neurosci Ther*. 2011;17:97–103.
17. Roberts C, Waterton J, Maynard J, Hockings P. How imaging biomarkers are transforming drug development. Drug Target Review website. https://www.drugtargetreview.com/article/32843/how-imaging-biomarkers-are-transforming-drug-development/. Published 2017. Accessed September 20, 2022.
18. United States Pharmacopeia (USP). *General chapter <1823>: positron emission tomography drugs–information*. USP-NF. Rockville, MD: United States Pharmacopeia;

2022. USP website. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/key-issues/general-chapter-1823-proposed-revision.pdf. Accessed November 1, 2022.

19. United States Pharmacopeia (USP). *General chapter <825>: radiopharmaceuticals – preparation, compounding, dispensing, and repackaging*. USP-NF. Rockville, MD: United States Pharmacopeia. USP website. https://www.usp.org/sites/default/files/usp/document/our-work/chemical-medicines/proposed-gc-825.pdf. Accessed November 2, 2022.

20. Current good manufacturing practice for positron emission tomography drugs. FDA website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=212. Updated March 29, 2022. Accessed September 20, 2022.

21. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general. FDA website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210. Updated March 29, 2022. Accessed September 20, 2022.

22. Current good manufacturing practice for finished pharmaceuticals. FDA website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211. Updated March 29, 2022. Accessed September 20, 2022.

23. *Guide for the Care and Use of Laboratory Animals*. 8th ed. National Academy Press; 2011.

24. Solon EG. Autoradiography techniques and quantification of drug distribution. *Cell Tissue Res*. 2015;360:87–107.

25. Alstrup AK, Smith DF. Anaesthesia for positron emission tomography scanning of animal brains. *Lab Anim*. 2013;47:12–18.

26. Rodnick ME, Hockley BG, Sherman P, et al. Novel fluorine-18 PET radiotracers based on flumazenil for GABA$_A$ imaging in the brain. *Nucl Med Biol*. 2013;40:901–905.

27. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med*. 2005;46:1023–1027.

28. Ertuk M, Van den Abbeele AD. Infrequent tumors of the gastrointestinal tract including gastrointestinal stromal tumor (GIST). *PET Clin*. 2008;3:207–215.

29. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. *Nature*. 2016;537:50–56.

30. Radioactive drug research committee (RDRC) program. FDA website. https://www.fda.gov/drugs/science-and-research-drugs/radioactive-drug-research-committee-rdrc-program. Updated June 9, 2021. Accessed September 20, 2022.

31. Investigational new drug (IND) application. FDA website. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application. Updated July 20, 2022. Accessed September 20, 2022.

32. Jackson IM, Lee SJ, Sowa AR, et al. Use of 55 PET radiotracers under approval of a radioactive drug research committee (RDRC). *EJNMMI Radiopharm Chem*. 2020;5:24.

33. Mosessian S, Duarte-Vogel SM, Stout DB, et al. INDs for PET molecular imaging probes: approach by an academic institution. *Mol Imaging Biol*. 2014;16:441–448.

34. Petrou M, Frey KA, Kilbourn MR, et al. In vivo imaging of human cholinergic nerve terminals with (−)-5-^{18}F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. *J Nucl Med*. 2014;55:396–404.

35. Saint-Georges Z, Zayed VK, Dinelle K, et al. First-in-human imaging and kinetic analysis of vesicular acetylcholine transporter density in the heart using [^{18}F]FEOBV PET. *J Nucl Cardiol*. 2021;28:50–54.

36. Xia Y, Eeles E, Fripp J, et al. Reduced cortical cholinergic innervation measured using [^{18}F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. *Neuroimage Clin*. 2022;34:102992.

37. Aghourian M, Legault-Denis C, Soucy JP, et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [^{18}F]-FEOBV. *Mol Psychiatry*. 2017;22:1531–1538.

38. Kanel P, van der Zee S, Sanchez-Catasus CA. Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: a [^{18}F]FEOBV PET study. *Aging Brain*. 2022;2:100039.

39. Carlucci G, Ippisch R, Slavik R. ^{68}Ga-PSMA-11 NDA approval: a novel and successful academic partnership. *J Nucl Med*. 2021;62:149–155.

40. Abghari-Gerst M, Armstrong WR, Nguyen K, et al. A comprehensive assessment of ^{68}Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. *J Nucl Med*. 2022;63:567–572.

41. Calais J, Gafita A, Eiber M, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ^{177}Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. *J Nucl Med*. 2021;62:1440–1446.

42. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. *N Engl J Med*. 2021;385:1091–1103.

43. Czernin J, Calais J. ^{177}Lu-PSMA617 and the VISION trial: one of the greatest success stories in the history of nuclear medicine. *J Nucl Med*. 2021;62:1025–1026.

44. Bergström M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. *Biol Psychiatry*. 2004;55:1007–1012.

45. van der Veldt AA, Smit EF, Lammertsma AA. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [^{11}C]docetaxel. *Front Oncol*. 2013;3:208.

46. Carpenter AP Jr, Pontecorvo MJ, Hefti FF, Skovronsky DM. The use of the exploratory IND in the evaluation and development of ^{18}F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. *Q J Nucl Med Mol Imaging*. 2009;53:387–393.